<?xml version="1.0" encoding="UTF-8"?>
<p class="p">A randomized, multicenter, placebo-controlled, double-blind clinical trial was carried out over a period of 25 weeks with 101 anxiety patients/non-psychotic origin [
 <xref rid="B368-molecules-24-01364" ref-type="bibr" class="xref">368</xref>]. All patients administered with either 110 mg kava extract (WS1490) or placebo three times a day. Drug receiving group showed a significant superiority in overall score of anxiety symptomatology assessed by Hamilton-Anxiety-Scale over placebo starting from week 8. Evenly distributed adverse events were observed rarely in both groups.
</p>
